
AtriCure, Inc.
NASDAQ•ATRC
CEO: Mr. Michael H. Carrel
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2005-08-05
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
連絡先情報
時価総額
$1.88B
PER (TTM)
-62.7
68
配当利回り
--
52週高値
$43.18
52週安値
$28.29
52週レンジ
順位67Top 97.6%
1.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2025 データ
売上高
$134.27M+15.84%
直近4四半期の推移
EPS
-$0.01-94.12%
直近4四半期の推移
フリーCF
$24.11M+47.05%
直近4四半期の推移
2025 Q3 決算ハイライト
主なハイライト
Revenue Growth Strong Worldwide revenue reached $394.03M for nine months, marking a 15.5% increase over prior year period.
Operating Income Achieved Switched to $208K operating income for three months ended September 30, reversing prior $7.41M operating loss.
Cash Flow Significantly Improved Net cash provided by operating activities totaled $37.31M for nine months, a substantial increase from $6.37M last year.
Net Loss Narrows Nine-month net loss significantly reduced to $13.20M compared to $29.13M reported in the comparable prior period.
リスク要因
Litigation Exposure Remains SentreHEART securityholder complaint alleges breach of contract seeking up to $260,000 plus interest; company vigorously defends.
Minimally Invasive Sales Decline Minimally invasive ablation sales dropped 33.2% in three months as physicians shift away from Hybrid procedures.
Increased R&D Investment Research and development expenses rose 22.0% (9M) due to personnel costs and $5,000K acquired IPR&D milestone payment.
Financing Obligation Created Failed sale-and-leaseback resulted in $6,250K financing obligation; future rental payments are projected through 2030.
見通し
New Pain Management Product Launched cryoICE® cryoXT™ probe in Q3 2025 for Cryo Nerve Block therapy in amputation pain management patients.
Clinical Trial Enrollment Complete LeAAPS IDE trial completed enrollment of 6,500 patients globally; BoxX-NoAF trial enrollment is ongoing.
Enhanced Physician Training Launched innovative training methods including virtual proctoring and new content for Advanced Practice Providers courses.
Tax Legislation Impact New OBBBA legislation made tax cuts permanent; company maintains full valuation allowance on U.S. deferred tax assets.
同業比較
売上高 (TTM)
STAA$94.91B
$3.93B
QDEL$2.72B
粗利益率 (最新四半期)
IMCR99.5%
QDEL93.2%
85.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| TWST | $3.01B | -39.1 | -16.6% | 28.8% |
| TXG | $2.42B | -31.5 | -10.3% | 8.5% |
| LMAT | $2.00B | 37.4 | 15.0% | 31.0% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい
深度リサーチ
次回決算:2026年2月11日
EPS:-$0.04
|売上高:-
財務レポート
財務データ
全年度
Form 10-Q - Q3 2025
会計期末: 2025年9月30日|提出日: 2025年10月30日|売上高: $134.27M+15.8%|EPS: $-0.01-94.1%予想を上回るForm 10-Q - Q2 2025
会計期末: 2025年6月30日|提出日: 2025年7月30日|売上高: $136.14M+17.1%|EPS: $-0.13-23.5%予想を上回るForm 10-Q - Q1 2025
会計期末: 2025年3月31日|提出日: 2025年4月30日|売上高: $123.62M+13.6%|EPS: $-0.14-50.0%予想を上回るForm 10-K - FY 2024
会計期末: 2024年12月31日|提出日: 2025年2月14日|売上高: $465.31M+16.5%|EPS: $-0.95-43.9%予想を下回るForm 10-Q - Q3 2024
会計期末: 2024年9月30日|提出日: 2024年10月30日|売上高: $115.91M+17.9%|EPS: $-0.17-15.0%予想を上回るForm 10-Q - Q2 2024
会計期末: 2024年6月30日|提出日: 2024年7月31日|売上高: $116.27M+15.2%|EPS: $-0.17+54.5%予想を上回るForm 10-Q - Q1 2024
会計期末: 2024年3月31日|提出日: 2024年5月2日|売上高: $108.85M+16.4%|EPS: $-0.28+100.0%予想を下回るForm 10-K - FY 2023
会計期末: 2023年12月31日|提出日: 2024年2月16日|売上高: $399.25M+20.8%|EPS: $-0.66+35.3%予想を下回る